New medication for Hair Loss... what coming?
Clascoterone (Breezula®) and the Next Generation of Hair Loss Treatments
By Dr Wayne Young, Young Hair Restoration
For nearly three decades, the medical treatment options for androgenetic alopecia (male and female pattern hair loss) have remained largely unchanged. Minoxidil and finasteride continue to be the mainstays of treatment, but a new wave of therapies is now emerging that may significantly expand our ability to prevent hair loss and stimulate regrowth.
Among the most anticipated developments is clascoterone 5% solution (Breezula®), alongside several novel medications that target hair loss through entirely different biological pathways.
Why New Hair Loss Treatments Are Needed
Current medical therapies can be highly effective, but they have limitations:
As our understanding of hair follicle biology improves, researchers are developing therapies that target the underlying causes of follicular miniaturisation more precisely than ever before.
What Is Clascoterone (Breezula®)?
Clascoterone is a topical androgen receptor antagonist. In simple terms, it blocks the effects of dihydrotestosterone (DHT) directly at the hair follicle without significantly affecting hormone levels throughout the rest of the body.
The same active ingredient is already approved in several countries as an acne treatment under the brand name Winlevi®, demonstrating an established safety profile when used topically.
How Does It Work?
Unlike finasteride, which reduces DHT production systemically, clascoterone acts locally on the scalp by:
This mechanism has made clascoterone particularly attractive for patients concerned about systemic side effects associated with oral therapies.
Phase III Results: Why Are Experts Excited?
In December 2025, Cosmo Pharmaceuticals announced positive Phase III trial results involving more than 1,400 men with androgenetic alopecia. The studies demonstrated statistically significant improvements in hair growth compared with placebo after long-term treatment. Regulatory submissions in the United States and Europe are now underway.
Key findings included:
If approved, clascoterone could become the first new major anti-androgen therapy for hair loss in many years.
Could Clascoterone Replace Finasteride?
Probably not entirely.
Instead, it is more likely to become:
Much will depend on long-term efficacy data and real-world results after approval.
Other Exciting Hair Loss Drugs on the Horizon
1. PP405 – Awakening Dormant Hair Follicles
PP405 is one of the most talked-about experimental treatments currently in development.
Unlike traditional therapies that focus primarily on DHT suppression or blood flow enhancement, PP405 aims to:
Researchers describe this as a regenerative approach rather than simply a maintenance treatment. Late-stage studies are expected to continue through 2026.
Many experts view PP405 as one of the most innovative developments currently being investigated.
2. GT20029 – Destroying the Androgen Receptor
GT20029 represents a completely new strategy.
Instead of merely blocking androgen receptors, it uses PROTAC technology designed to:
While still under clinical investigation, this technology has attracted significant attention because it could offer a fundamentally different way to address androgen-driven hair loss.
3. HMI-115 – The Prolactin Antibody
HMI-115 is a monoclonal antibody initially developed for other medical indications.
Researchers discovered that prolactin signalling may play a role in follicular cycling and androgenetic alopecia. Early Australian studies showed encouraging safety and efficacy signals, leading to larger Phase II investigations.
Potential advantages include:
However, it remains several years away from possible clinical availability.
4. Improved Oral Minoxidil Formulations
Oral minoxidil has become increasingly popular worldwide, but cardiovascular side effects remain a concern in some patients.
Several pharmaceutical companies are now developing:
These next-generation formulations may improve convenience and safety while preserving efficacy.
What This Means for Patients Today
While these developments are exciting, it is important to remain realistic.
Most investigational therapies:
For patients currently experiencing hair loss, delaying treatment while waiting for future therapies often results in further follicular miniaturisation and donor depletion.
The most successful approach remains:
The Future of Hair Restoration
The next five years may represent the most significant period of innovation in hair loss treatment since the introduction of finasteride and minoxidil.
Clascoterone appears poised to become the first major new anti-androgen therapy, while regenerative treatments such as PP405 and receptor-degrading technologies such as GT20029 may eventually redefine how we approach androgenetic alopecia.
For patients and doctors alike, the future of hair restoration has never looked more promising.
Interested in understanding which current and emerging treatments may be suitable for your hair loss? Contact Young Hair Restoration for a personalised medical assessment and long-term hair restoration plan.
By Dr Wayne Young, Young Hair Restoration
For nearly three decades, the medical treatment options for androgenetic alopecia (male and female pattern hair loss) have remained largely unchanged. Minoxidil and finasteride continue to be the mainstays of treatment, but a new wave of therapies is now emerging that may significantly expand our ability to prevent hair loss and stimulate regrowth.
Among the most anticipated developments is clascoterone 5% solution (Breezula®), alongside several novel medications that target hair loss through entirely different biological pathways.
Why New Hair Loss Treatments Are Needed
Current medical therapies can be highly effective, but they have limitations:
- Not all patients respond adequately
- Results can take many months
- Continuous treatment is required
- Some patients experience unwanted side effects
- Existing treatments primarily slow progression rather than fully restoring lost hair
As our understanding of hair follicle biology improves, researchers are developing therapies that target the underlying causes of follicular miniaturisation more precisely than ever before.
What Is Clascoterone (Breezula®)?
Clascoterone is a topical androgen receptor antagonist. In simple terms, it blocks the effects of dihydrotestosterone (DHT) directly at the hair follicle without significantly affecting hormone levels throughout the rest of the body.
The same active ingredient is already approved in several countries as an acne treatment under the brand name Winlevi®, demonstrating an established safety profile when used topically.
How Does It Work?
Unlike finasteride, which reduces DHT production systemically, clascoterone acts locally on the scalp by:
- Blocking androgen receptors within hair follicles
- Reducing the follicle’s response to DHT
- Potentially slowing or reversing follicular miniaturisation
- Minimising systemic hormonal exposure due to rapid local metabolism
This mechanism has made clascoterone particularly attractive for patients concerned about systemic side effects associated with oral therapies.
Phase III Results: Why Are Experts Excited?
In December 2025, Cosmo Pharmaceuticals announced positive Phase III trial results involving more than 1,400 men with androgenetic alopecia. The studies demonstrated statistically significant improvements in hair growth compared with placebo after long-term treatment. Regulatory submissions in the United States and Europe are now underway.
Key findings included:
- Significant increases in target area hair counts
- Continued improvement with longer treatment duration
- Good overall tolerability
- Minimal systemic exposure due to local scalp activity
If approved, clascoterone could become the first new major anti-androgen therapy for hair loss in many years.
Could Clascoterone Replace Finasteride?
Probably not entirely.
Instead, it is more likely to become:
- An alternative for patients who cannot tolerate finasteride
- A complementary treatment used alongside minoxidil
- Part of combination protocols for higher-risk patients
- An option for younger patients seeking a non-systemic approach
Much will depend on long-term efficacy data and real-world results after approval.
Other Exciting Hair Loss Drugs on the Horizon
1. PP405 – Awakening Dormant Hair Follicles
PP405 is one of the most talked-about experimental treatments currently in development.
Unlike traditional therapies that focus primarily on DHT suppression or blood flow enhancement, PP405 aims to:
- Reactivate dormant follicular stem cells
- Restart hair growth cycles
- Potentially regenerate hair in areas that have significantly miniaturised
Researchers describe this as a regenerative approach rather than simply a maintenance treatment. Late-stage studies are expected to continue through 2026.
Many experts view PP405 as one of the most innovative developments currently being investigated.
2. GT20029 – Destroying the Androgen Receptor
GT20029 represents a completely new strategy.
Instead of merely blocking androgen receptors, it uses PROTAC technology designed to:
- Target androgen receptors for degradation
- Reduce receptor levels within follicular cells
- Potentially provide stronger anti-androgen activity than receptor blockade alone
While still under clinical investigation, this technology has attracted significant attention because it could offer a fundamentally different way to address androgen-driven hair loss.
3. HMI-115 – The Prolactin Antibody
HMI-115 is a monoclonal antibody initially developed for other medical indications.
Researchers discovered that prolactin signalling may play a role in follicular cycling and androgenetic alopecia. Early Australian studies showed encouraging safety and efficacy signals, leading to larger Phase II investigations.
Potential advantages include:
- Novel mechanism of action
- Potential benefit for both men and women
- Infrequent dosing schedules compared with daily medications
However, it remains several years away from possible clinical availability.
4. Improved Oral Minoxidil Formulations
Oral minoxidil has become increasingly popular worldwide, but cardiovascular side effects remain a concern in some patients.
Several pharmaceutical companies are now developing:
- Extended-release formulations
- More predictable drug delivery systems
- Reduced peak-dose cardiovascular effects
These next-generation formulations may improve convenience and safety while preserving efficacy.
What This Means for Patients Today
While these developments are exciting, it is important to remain realistic.
Most investigational therapies:
- Have not yet received regulatory approval
- Require further long-term safety data
- May take several years before becoming widely available
- Will likely work best when combined with comprehensive hair restoration strategies
For patients currently experiencing hair loss, delaying treatment while waiting for future therapies often results in further follicular miniaturisation and donor depletion.
The most successful approach remains:
- Early diagnosis
- Comprehensive medical assessment
- Individualised treatment planning
- Evidence-based medical therapy
- Hair transplantation when appropriate
The Future of Hair Restoration
The next five years may represent the most significant period of innovation in hair loss treatment since the introduction of finasteride and minoxidil.
Clascoterone appears poised to become the first major new anti-androgen therapy, while regenerative treatments such as PP405 and receptor-degrading technologies such as GT20029 may eventually redefine how we approach androgenetic alopecia.
For patients and doctors alike, the future of hair restoration has never looked more promising.
Interested in understanding which current and emerging treatments may be suitable for your hair loss? Contact Young Hair Restoration for a personalised medical assessment and long-term hair restoration plan.